Compare CYBN & BIOA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CYBN | BIOA |
|---|---|---|
| Founded | 2019 | 2015 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Pharmaceuticals and Biotechnology | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 298.9M | 175.7M |
| IPO Year | N/A | 2024 |
| Metric | CYBN | BIOA |
|---|---|---|
| Price | $6.62 | $12.97 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 4 |
| Target Price | ★ $74.50 | $11.33 |
| AVG Volume (30 Days) | ★ 610.5K | 403.7K |
| Earning Date | 11-13-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $5,917,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.81 | $2.88 |
| 52 Week High | $10.73 | $13.10 |
| Indicator | CYBN | BIOA |
|---|---|---|
| Relative Strength Index (RSI) | 60.06 | 83.65 |
| Support Level | $5.70 | $12.00 |
| Resistance Level | $6.20 | $13.10 |
| Average True Range (ATR) | 0.35 | 0.72 |
| MACD | 0.08 | 0.32 |
| Stochastic Oscillator | 85.82 | 97.20 |
Cybin Inc is a biopharmaceutical company involved in creating safe and effective therapeutics for patients to address a multitude of mental health issues. The Company is a clinical-stage neuropsychiatric company focused on advancing therapies, delivery mechanisms, novel compounds, and protocols as potential treatments for various psychiatric and neurological conditions. The Company is developing technologies and delivery systems aimed at improving the pharmacokinetics of its proprietary molecules while retaining the therapeutic benefit. These new molecules and delivery systems are expected to be studied through clinical trials to confirm safety and efficacy.
Bioage Labs Inc is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of human aging. Its focus is metabolic disease, one of the greatest healthcare challenges. The pipeline Products of the company are NLRP3 inhibitors, APJ against, and others.